Legal & General Group’s Ascendis Pharma A/S ASND Stock Holding History

Legal & General Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.72M	Sell	6,454 -6,715	-51%	-$1.57M	﹤0.01%	2017
2026 Q1	$3.01M	Sell	13,169 -1,614	-11%	-$362K	﹤0.01%	1746
2025 Q4	$3.15M	Buy	14,783 +13,359	+938%	+$2.76M	﹤0.01%	1796
2025 Q3	$283K	Buy	1,424 +1,119	+367%	+$209K	﹤0.01%	2561
2025 Q2	$52.6K	Sell	305 -472	-61%	-$76.9K	﹤0.01%	2704
2025 Q1	$121K	Sell	777 -16,905	-96%	-$2.41M	﹤0.01%	2653
2024 Q4	$2.43M	Buy	17,682 +16,628	+1,578%	+$2.19M	﹤0.01%	1892
2024 Q3	$157K	Hold	1,054	–	–	﹤0.01%	2700
2024 Q2	$144K	Buy	1,054 +189	+22%	+$25.7K	﹤0.01%	2704
2024 Q1	$131K	Buy	865 +667	+337%	+$95.2K	﹤0.01%	2721
2023 Q4	$24.9K	Sell	198 -840	-81%	-$83.7K	﹤0.01%	2947
2023 Q3	$97.2K	Buy	+1,038	New	+$97.1K	﹤0.01%	2831

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Legal & General Group's ASND Position: Q2 2026 in Review

Legal & General Group reduced its Ascendis Pharma A/S (ASND) stake by 51% in Q2 2026, selling an estimated $1.57M and leaving 6,454 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Legal & General Group first reported a position in ASND in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.15M in Q4 2025. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Legal & General Group held 6,454 shares of Ascendis Pharma A/S worth $1.72M as of Q2 2026.
Legal & General Group sold 6,715 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.57M.
Ascendis Pharma A/S made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2017 holding.
Legal & General Group first reported a position in Ascendis Pharma A/S in Q3 2023 and has held it in 12 quarters since.
Legal & General Group's Ascendis Pharma A/S position peaked at $3.15M in Q4 2025.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.